• Featured Product
  • KD/KO Validated

ARID3A Polyclonal antibody

ARID3A Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, IF/ICC, IP, ChIP, ELISA

Conjugate

Unconjugated

Cat no : 14068-1-AP

Synonyms

DRIL1, Dead ringer-like protein 1, BRIGHT, B-cell regulator of IgH transcription, AT-rich interactive domain-containing protein 3A


☆対象製品が30%オフ!組換えタンパク質&免染用試薬 >>> キャンペーン実施中!


Tested Applications

Positive WB detected inK-562 cells, mouse placenta tissue
Positive IP detected inK-562 cells
Positive IHC detected inhuman colon cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF/ICC detected inHepG2 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:300-1:1200
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

14068-1-AP targets ARID3A in WB, IHC, IF/ICC, IP, ChIP, ELISA applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Cited Reactivityhuman, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen ARID3A fusion protein Ag5124 相同性解析による交差性が予測される生物種
Full Name AT rich interactive domain 3A (BRIGHT-like)
Calculated molecular weight 63 kDa
Observed molecular weight 75 kDa
GenBank accession numberBC060828
Gene symbol ARID3A
Gene ID (NCBI) 1820
RRIDAB_2060390
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

ARID3A is a nuclear matrix-associated transcription factor that stimulates immunoglobulin heavy chain (IgH) expression and Cyclin E1/E2F-dependent cell cycle progression. It activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix attachment regions (MARs) flanking the IgH intronic enhancer (Emu) (PMID:17386101). It is the founder of the 13-member (in humans) ARID (AT-Rich Interaction Domain) family, which share a highly conserved DNA binding domain, but functions in diverse biological processes such as cell cycle regulated events, epigenetic post-translational modification, and chromatin remodeling (PMID:15927959,11959810,11283269). The expression molecular weight observed is consistent with what has been described in the literature (PMID: 15922553, 19436740).

Protocols

Product Specific Protocols
WB protocol for ARID3A antibody 14068-1-APDownload protocol
IHC protocol for ARID3A antibody 14068-1-APDownload protocol
IF protocol for ARID3A antibody 14068-1-APDownload protocol
IP protocol for ARID3A antibody 14068-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIHC

Cell Rep Med

Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application

Authors - Xiaoxue Ren
mouseIHC

PLoS Genet

Let-7 Represses Carcinogenesis and a Stem Cell Phenotype in the Intestine via Regulation of Hmga2.

Authors - Blair B Madison
humanWB,IP

Carcinogenesis

ARID3A promotes the development of colorectal cancer by upregulating AURKA.

Authors - Jing Tang
  • KD Validated
humanWB,IHC

Ann Surg Oncol

High Expression of AT-Rich Interactive Domain 3A (ARID3A) is Associated with Good Prognosis in Colorectal Carcinoma.

Authors - Meiying Song
human,mouseWB,IF

Cell Biol Int

ARID3A plays a key regulatory role in palmitic acid-stimulated milk fat synthesis in mouse mammary epithelial cells

Authors - Xudong Guo
  • KD Validated
humanWB,ChIP

Cell Biol Int

ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3.

Authors - Yafei Li